Dr. David Fajgenbaum

You know, do you want to work with us on this?

And not surprisingly, there's a lot of enthusiasm because, I mean, you think about something like Bachman Bup, those kids, like,

the couple dozen that have ever been found, their parents probably weren't expecting that there would be sort of a, you know, full blown effort for their condition.

Um, and again, thankful to Dr. Bachman and Dr. Bup for, for all the work they've done and we're excited to work with them.

That's, that's incredible, man.

It's a great question because, you know, in the U.S., and I've wondered this too, like in the U.S., we do what are called autologous stem cell transplants for people with cancer all the time.

That cancer I mentioned, multiple myeloma, you oftentimes treat people with their own stem cells.

Like you basically take their stem cells out, you give them chemo, and then you give them their stem cells back.

We do that.

We do what's called an allogeneic stem cell transplant where you get someone else's stem cells, like their bone marrow stem cells,

And that can sometimes be curative for leukemia and for lymphomas.

So we're doing it already in some settings, but I'm not sure why some of these other settings it hasn't come forward.

Because some of the stem cell work with autologous and allogeneic stem cells,

It's been 20 years that we've been doing that in the US.

So I'm not sure why, because what that tells me is that like the US FDA is willing and they're open when these sorts of stem cells are effective in certain ways.

Maybe it's for cancer, maybe there's a different sort of risk profile, because there's a big risk when you do these stem cell transplants for cancer.

Like you have like a 10% chance of death within that year from the treatment.

you got a 90% chance that you might be, not 90% cured, but you have a high chance you might be cured, but you got a 10% chance you're going to die from the stem cell transplant.

And so it might be that the FDA is willing to sort of put a stamp on that sort of a risk when like you've got a deadly leukemia and maybe less willing to like put that sort of a risk if it's not as deadly.

And again, that's not from any data that I have, but that's the only way I can wrap my head around it is like, why do we do it here, but we don't do it over there?